GLP-1 Medications
GLP-1 (Glucagon-like peptide-1) receptor agonists are a class of pharmaceutical medications primarily used for the treatment of type 2 diabetes and obesity. Prominent brand names include Ozempic, Wegovy, and Mounjaro.
Market Impact
With an estimated 18% of U.S. adults reporting past or present use, these medications are acting as a massive external disrupter to the global food and beverage industry. By delaying gastric emptying, inducing early satiety, and altering the brain’s reward pathways, GLP-1 medications fundamentally change consumer behavior. They are projected to reduce traditional beverage spending by $48 billion over the next decade.
Beverage Industry Disruption
The widespread adoption of GLP-1 medications is driving two major trends in the beverage sector:
- glp-1-impact-on-alcohol-consumption: Users experience a natural reduction in cravings for alcohol, leading to a 30% to 50% drop in weekly alcoholic drinks and accelerating the trend of damp-drinking.
- The Rise of Functional Beverages: Because users have suppressed appetites, they must hyper-focus on nutrient density. This has led to a boom in functional beverages, particularly prebiotic sodas (to combat gastrointestinal side effects) and high-protein drinks (to prevent lean muscle loss). This shift has also exposed vulnerabilities in traditional categories, leading to the-diet-soda-paradox.